Drug Trial Radar · NCT02144415
A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
May 1, 2014
Primary completion
Jul 1, 2014
Study completion Jul 1, 2014
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- May 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This single-center study will be a single-dose, randomized, double-blind, placebo- and active-controlled crossover study with a single inpatient treatment visit. The abuse potential of single oral doses of EB-1020 IR (400 mg, 800 mg) will be compared with that of placebo and d-amphetamine (20 mg, 40 mg; active control) in healthy recreational stimulant users. Subjects will participate in a medical Screening visit (Visit 1), one 4-day inpatient Qualification Phase (Visit 2), one 11-day inpatient Treatment Phase (Visit 3), and a safety Follow-up visit (Visit 4).
Conditions
- Healthy Volunteers
- Drug Users
Interventions
EB-1020 400 mgDrug
4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
EB-1020 800 mgDrug
8 x EB-1020 100-mg capsules
lisdexamfetamine 150 mgDrug
3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
d-amphetamine 40 mgDrug
4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
PlaceboDrug
8 x matching placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum effect (Emax) on Drug Liking visual analog scale (VAS)Time frame: within 24 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vince and Associates Clinical Research, Inc.
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.